Cover Image

Clinical decision points for two plasma p‐tau217 laboratory developed tests in neuropathology confirmed samples

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Anna E. Mammel, Ging‐Yuek Robin Hsiung, Ali Mousavi, Kelsey Hallett, Ian R. Mackenzie, Veronica Hirsch‐Reinshagen, Don Biehl, Pradip Gill, Mary Encarnacion, Hans Frykman
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Diagnostic and analytical performance of plasma pTau181 and 217 in a clinical laboratory
by: Anna Mammel, et al.
Published: (2024)

Comparison of three plasma p‐tau217 assays to detect PET‐confirmed Alzheimer's pathologies
by: Sayo Matsuura, et al.
Published: (2026)

Clinical and neuropathological associations of plasma Aβ42/Aβ40, p‐tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders
by: Binita Rajbanshi, et al.
Published: (2025)

Diagnostic utility of plasma p‐tau217 differs by Alzheimer's disease tau‐based subtypes
by: Seyed Hani Hojjati, et al.
Published: (2025)

Preclinical dementia rating scores are associated with plasma phosphorylated tau‐217
by: Qi Huang, et al.
Published: (2025)

Cross‐sectional study of plasma phosphorylated tau 217 in persons without dementia
by: Toni T. Saari, et al.
Published: (2025)

Performance of plasma p‐tau217 and NfL in an unselected memory clinic setting
by: Rebecca Z. Rousset, et al.
Published: (2024)

Associations of plasma phosphorylated tau217 with cognitive impairment and brain microstructural alterations in Alzheimer's disease
by: Miguel Ángel Rivas‐Fernández, et al.
Published: (2026)

Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
by: Adam H. Dyer, et al.
Published: (2025)

Plasma p‐tau217 and APOE genotype: Prodromal Alzheimer's disease staging
by: Ann M. Stowe, et al.
Published: (2026)

Evaluation of Plasma Phosphorylated Tau217 for Differentiating Alzheimer's Disease
by: Anna Mammel, et al.
Published: (2025)

Plasma p‐tau217 for Alzheimer's disease diagnosis: a memory clinic implementation approach
by: Giorgia Brodini, et al.
Published: (2026)

Clinical validation of the Lilly SP‐X P‐tau217 assay: Performance in underrepresented cohorts
by: Michael E. Hodsdon, et al.
Published: (2025)

Plasma p‐tau217 and cognitive impairment: Evaluating biomarker equity across racial/ethnic groups in HABS‐HD
by: Cellas A. Hayes, et al.
Published: (2026)

P‐tau217 testing impact on intended management of patients presenting with cognitive impairment: A randomized clinical utility study
by: Samantha C. Burnham, et al.
Published: (2025)

Marital dissolution and cognition: The mediating effect of Aβ neuropathology
by: Avinash Chandra, et al.
Published: (2024)

Clinical and demographic factors modify the association between plasma phosphorylated tau‐181 and cognition
by: Corey J. Bolton, et al.
Published: (2024)

Alzheimer's disease neuropathology and longitudinal change in subjective cognitive complaints
by: Alisa Bannerjee, et al.
Published: (2025)

Digital cognition plus plasma p‐Tau217 and Aβ42/40 powerfully predict Alzheimer's progression
by: Ahmet Begde, et al.
Published: (2026)

Clinical performance of scalable automated p‐tau 217 multi‐analyte algorithmic blood test with reduced intermediate zone using multiplexed digital immunoassay
by: David H. Wilson, et al.
Published: (2025)

Associations of plasma p‐Tau217 with cognitive domain performance in clinically unimpaired participants: Evidence from HABS‐HD
by: Zara Najmi, et al.
Published: (2026)

Body composition and plasma total‐tau, neurofilament light chain, and amyloid‐β: A population‐based study
by: Tosca O. E. de Crom, et al.
Published: (2024)

Association of plasma GFAP with elevated brain amyloid is dependent on severity of white matter lesions in an Asian cognitively impaired cohort
by: Joyce R. Chong, et al.
Published: (2024)

Elevated tau in the piriform cortex in Alzheimer's but not Parkinson's disease using PET‐MR
by: Hossein Moein Taghavi, et al.
Published: (2024)

Subjective memory concerns and AD/ADRD plasma biomarker associations in HABS‐HD
by: Kelsey R. Thomas, et al.
Published: (2026)

Reduced plasma hexosylceramides in frontotemporal dementia are a biomarker of white matter integrity
by: Oana C. Marian, et al.
Published: (2025)

Prevalence of cerebral amyloid angiopathy and its correlation with Alzheimer's disease and cognition in an autopsy‐confirmed cohort from China
by: Xiang‐Sha Yin, et al.
Published: (2025)

Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia
by: Cassandra Marotta, et al.
Published: (2025)

Survey among experts on the future role of tau‐PET in clinical practice and trials
by: Marie R. Vermeiren, et al.
Published: (2024)

Identifying cognitive test scores associated with early tau burden in Alzheimer's disease
by: Caitlin M. Terao, et al.
Published: (2025)

Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology
by: Lara Blömeke, et al.
Published: (2024)

sTREM2 in discordant CSF Aβ42 and p‐tau181
by: Danni Li, et al.
Published: (2025)

Resistance and resilience to tau pathology in Alzheimer's disease: Effects of age, sex, and APOE alleles
by: Yury Loika, et al.
Published: (2024)

Correction to “Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology”
Published: (2024)

Explaining variability in early stages of [18F]‐flortaucipir tau‐PET binding: Focus on sex differences
by: Dario Bachmann, et al.
Published: (2024)

Hallucinations and delusions are associated with elevated tau PET signal independent of age, clinical severity, and amyloid burden
by: Aubrey S Johnson, et al.
Published: (2026)

Association of item‐level responses to cognitive function index with tau pathology and hippocampal volume in the A4 Study
by: Idris Demirsoy, et al.
Published: (2025)

Investigating the amyloid–tau–neurodegeneration framework in Alzheimer's disease using semi‐supervised multimodal imaging data fusion
by: You Cheng, et al.
Published: (2026)

Classifying mild cognitive impairment from normal cognition: fMRI complexity matches tau PET performance
by: Kay Jann, et al.
Published: (2025)

Genetic associations of plasma proteomics with dementia subtypes and neuroimaging markers
by: Ahmed M. Salih, et al.
Published: (2025)